Harbinger Health Presents Clinical Data at ASCO Supporting RESOLVE™ as a New Blood-Based Category for Evaluation of Suspected Cancer
Presentation highlights test performance in individuals presenting with signs, symptoms, or findings suggestive of cancer, reflecting the real-world clinical context RESOLVE™ is designed to address CAMBRIDGE, Mass., May 29, 2026 /PRNewswire/ -- Harbinger Health, a biotechnology company...
Presentation highlights test performance in individuals presenting with signs, symptoms, or findings suggestive of cancer, reflecting the real-world clinical context RESOLVE™ is designed to address CAMBRIDGE, Mass., May 29, 2026 /PRNewswire/ -- Harbinger Health, a biotechnology company...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.